At CFO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top New York based CFO’ operating in the Biotechnology space. If you think a CFO’ is missing from this list, feel free to contact our editor on [email protected].
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Han Kieftenbeld
Chief Financial Officer of Amyris
Han Kieftenbeld joined Amyris as Chief Financial Officer in March 2020. He brings over 25 years of international business leadership, finance and operations experience in food, health and nutrition end-markets. Most recently, from April 2016 to April 2019, Mr. Kieftenbeld served as Senior Vice President and Chief Financial Officer of Innophos Holdings, Inc., a leading international science-based producer of essential ingredients for health and nutrition, food and beverage and industrial brands. From June 2014 to July 2015, Mr. Kieftenbeld served as the Global Chief Financial Officer at AB Mauri, a worldwide leader in bakery ingredients. Prior to that, Mr. Kieftenbeld held finance and operations roles of increasing reach and impact, including serving as Global Chief Procurement Officer of Ingredion Incorporated, and Global Chief Financial Officer of National Starch. Mr. Kieftenbeld started his career at Unilever in the Netherlands. In 2006, Mr. Kieftenbeld earned a joint master’s degree from New York University Stern School of Business, London School of Economics and Political Science, and the HEC School of Management, Paris. He holds a B.S. in Business Economics and Accounting from Windesheim University in the Netherlands.
Follow Han Kieftenbeld:
About Amyris: Amyris Biotechnologies specializes in creating renewable products focusing on fuels and chemicals.
Neil Edwards
Chief Financial Officer of Vesselon
Neil Edwards is the CEO of Cellufun. Edwards served as the founding CEO of dotMobi, a mobile web services company, where he grew the company from a start-up to a multi-million dollar organization. At dotMobi he built a global customer base with multiple channel platforms and content partners that generated significant recurring revenue streams. Additionally,Mr. Edwards was instrumental in building a consortium of leading mobile brands including Nokia, Vodafone, Google, Telefonica, Telecom Italia, T-Mobile, Orascom, Microsoft, Visa and many others. Prior to dotMobi, he was instrumental in the growth of VeriSign and infoUSA,having served in senior leadership positions within both organizations.
Follow Neil Edwards:
About Forbes, Vesselon: Vesselon is a medical device company developing novel therapeutic Immuno-Oncology complexes.
Brett Kaplan
Chief Financial Officer of Prevail Therapeutics
Brett Kaplan is our Chief Financial Officer. Prior to Prevail, he was Managing Director at Evercore, where he spent eight years concentrating on biopharma M&A and equity financings. Prior to Evercore, Brett was an Equity Research Analyst at Cowen, where he covered large cap pharmaceuticals. Earlier in his career, he held senior positions at Cubist and Lilly focused on corporate and business development. Brett holds an MBBCh and an MBA from the University of Witwatersrand in South Africa.
Follow Brett Kaplan:
About Prevail Therapeutics: Prevail Therapeutics is a biotechnology company focused on developing novel gene therapies for patients with Parkinson’s disease.
Adam Cutler
Chief Financial Officer of Molecular Templates
Adam Cutler has served as Molecular Templates’ Chief Financial Officer since November 2017.Prior to joining Molecular Templates, he was Senior Vice President of Corporate Affairs at Arbutus Biopharma from 2015-2017, where his responsibilities included investor relations, business development, and corporate finance. From 2012-2015, he was a Managing Director for The Trout Group and Trout Capital, where he executed financings and advised life science companies on investor relations, capital raising, and business development. From 2000-2011, he was a biotechnology equity research analyst at Credit Suisse, Canaccord Genuity, JMP Securities, and Bank of America Merrill Lynch. He also worked in healthcare consulting at The Frankel Group and Ernst & Young. He currently serves on the Board of Directors for Inmed Pharmaceuticals and Navidea Biopharmaceuticals. He received his B.A. in Economics from Brandeis University.
Follow Adam Cutler:
About Molecular Templates: Molecular Templates develops novel therapeutic compounds for cancer.
Daniel Schneiderman
Chief Financial Officer of First Wave BioPharma
Follow Daniel Schneiderman:
About First Wave BioPharma: First Wave BioPharma aims to become a leader in developing non-systemic, recombinant protein therapies.
Jaime Bartushak
CFO of Citius Pharmaceuticals
Follow Jaime Bartushak:
About Citius Pharmaceuticals: Citius Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products.
Paul Herendeen
Executive Vice President and Chief Financial Officer of Zoetis India Ltd
Paul Herendeen is executive vice president and chief financial officer (EVP and CFO) of Zoetis. In his role, Herendeen oversees the company’s Finance and Information Technology organizations and serves as part of the Zoetis Executive Team, reporting to CEO Juan Ramón Alaix. Herendeen brings more than 30 years of broad financial experience and leadership to his role at Zoetis, including 16 years as CFO of Warner Chilcott and MedPointe. From 2005 to 2013, Herendeen served as CFO at Warner Chilcott, a specialty pharmaceuticals company, which had a successful IPO in 2006, grew its revenue and profitability, and was acquired by Actavis in 2013. He joined Warner Chilcott after four years as EVP and CFO of MedPointe, a privately held health care company. He had been Warner Chilcott’s CFO from 1998 until 2000, joining the company after representing one of its lead investors on Warner Chilcott’s Board of Directors. Herendeen helped grow the company’s revenues and conduct its first successful IPO, and later helped complete the company’s acquisition by Galen PLC. From 1989 to 1998, Herendeen spent nine years as a principal investor at both Dominion Income Management and Cornerstone Partners, where he worked on investments as well as mergers and acquisitions for the firms and their portfolio companies. He also spent the early part of his career in banking and public accounting, having held various positions with the investment banking group of Oppenheimer & Company, the capital markets group of Continental Bank Corporation, and as a senior auditor with Arthur Andersen & Company. Herendeen earned a Master of Business Administration (MBA) from the University of Virginia’s Darden School of Business, and holds a bachelor’s degree in Business Administration from Boston College.
Follow Paul Herendeen:
About Bausch Health, Zoetis India Ltd: Zoetis provides healthcare services for animal.
Ethan Einwohner
Chief Financial Officer of Specified Testing Labs
I Ethan Einwohner formed Specified Testing Labs, LLC, a roll-up of environmental testing laboratories, in August 2013. Under Specified, Ethan led the acquisitions of the testing lab assets of: International Hydronics Corporation (Oct 2013); New Jersey Analytical Labs (Nov, 2013), CNA Environmental (Dec 2013); and Smith Environmental Labs (Apr 2014). At Specified, Ethan manages all financial aspects of the firm and has responsibilities for its acquisition and integration activities. With his laboratory operations team, Ethan forms and executes company strategy .
Follow Ethan Einwohner:
About CNA Environmental, Recurrent Capital Bridge Fund, Specified Testing Labs: Specified Testing Laboratories, LLC is a holding company of testing laboratories and related operating companies. Formed in September .
Alexander Casdin
Chief Operating Officer & Chief Financial Officer of Epirium
Alexander Casdin is the Chief Financial Officer (CFO) of Epirium Bio. He has broad financial and operational expertise, with more than 20 years of experience as a healthcare executive and investor. Prior to joining Epirium, Mr. Casdin was founder, Chief Executive Officer (CEO) and portfolio manager of Reneo Capital Management LP, a successful healthcare investment fund. He previously served as CFO of Sophiris Bio, Inc. and Vice President of Finance for Amylin Pharmaceuticals. Mr. Casdin was a founder and senior advisor at Casdin Advisors, LLC; CEO and portfolio manager at Cooper Hill Partners, LLC, a healthcare investment fund; and portfolio manager of Pequot Capital Management’s healthcare fund. Earlier, he worked at the Dreyfus Corporation as a senior managing analyst covering pharmaceuticals, biotechnology and medical devices. Mr. Casdin has been on the board of directors for multiple life science companies including Erasca, Inc., Dusa Pharmaceuticals, Inc., and Ignyta, Inc. Mr. Casdin received an M.B.A from Columbia Business School and a B.A. in political science from Brown University.
Follow Alexander Casdin:
About Epirium, Epirium: Epirium Bio is a clinical stage bio pharmaceutical company.
Douglas Larson
Group Chief Financial Officer of Beyond Air
Douglas Larson is the Group Chief Financial Officer at Beyond Air.
Follow Douglas Larson:
About Beyond Air: Beyond Air is a biotechnology company focused on the development of drugs for the treatment of lung infections.
Algimantas Chesonis
CFO of Sweetwater Energy
Algimantas Chesonis currently works as Chief Financial Officer at Sweetwater Energy.
Follow Algimantas Chesonis:
About Sweetwater Energy: Sweetwater Energy is a company that produces concentrated sugar from multiple non-food plant materials.
Algimantas Chesonis
CFO of Sweetwater Energy
Algimantas Chesonis currently works as Chief Financial Officer at Sweetwater Energy.
Follow Algimantas Chesonis:
About Sweetwater Energy: Sweetwater Energy is a company that produces concentrated sugar from multiple non-food plant materials.
Peter Collum
Chief Financial Officer and Chief Business Officer of Pharnext
More than 17 years’ experience in healthcare investment banking focused on M&A, financing and business development transactions. Previously partner at MTS Health Partners for public and private life sciences companies both in the US and abroad, and worked in the healthcare investment banking group at Bank of America. Started at Roche as an engineer.
Follow Peter Collum:
About Pharnext: Pharnext is a biopharmaceutical company engaged in the development of treatments for severe neurological diseases.
David Cordo
CFO of Metamark Genetics
Mr. Cordo began his career in the life sciences industry in 1990. He held senior management positions in finance at Biogen Idec during his seven-year tenure where he put in place the financial infrastructure for the worldwide commercial launch of Avonex. For seven years, he was the Treasurer of Millennium Pharmaceuticals. At Millennium, he led finance teams in the raising of an $800 million follow-on equity offering and a $400 million convertible debt offering. He also led finance teams for three acquisitions. Dave has been interim chief financial officer for several venture capital backed life science companies, including Dicerna Pharmaceuticals, Epizyme, Inc., Link Medicine Corporation, TransForm Pharmaceuticals, Avila Therapeutics and Alinea Pharmaceuticals, and consulting on strategic financial issues for public and private life science companies. He is a Certified Public Accountant and holds an M.B.A. degree from Nichols College and a B.S.B.A. degree from Stonehill College. He is an active member of the Executive Committee of the Wake Forest University Parents’ Council and consults for several charitable organizations.
Follow David Cordo:
About Metamark Genetics, Novartis, Potenza Therapeutics, Semma Therapeutics: Metamark Genetics develops prognostic and predictive diagnostic tests that enable personalized treatment planning for cancer patients.
Melissa Epperly
Chief Financial Officer of Psioxus Therapeutics
Melissa Epperly is a senior finance executive with deep healthcare experience. Prior to joining PsiOxus, Melissa was CFO and Head of Business Development at R-Pharm US, a commercial-stage oncology pharmaceutical company based in Princeton, NJ. At R-Pharm US she led corporate and business development, leading the integration of the asset purchase of Ixempra ® (a metastatic breast cancer treatment) from Bristol-Myers Squibb. Previously, Melissa was a Director at Anchorage Capital Group, a credit-focused hedge fund, where she drove operational excellence in their portfolio companies to facilitate and enable exponential growth. Prior to that she was a Vice President at Goldman Sachs in equity research where she helped develop, build, and commercialize a novel, global equity research product for long-term investing, GS SUSTAIN, in the US and Europe. Before joining Goldman Sachs she was a management consultant with Bain & Company in New York and London, focused on international and US based pharmaceutical clients and private equity. She previously worked at Morgan Stanley in New York in healthcare investment banking and banking management, enabling pharmaceutical and biotech companies to accelerate growth through strategic MandA and capital raising. Melissa holds an MBA from Harvard Business School and BA in Biochemistry and Economics from the University of Virginia, where she graduated Phi Beta Kappa.
Follow Melissa Epperly:
About Psioxus Therapeutics: Psioxus Therapeutics is a cancer gene therapy company delivers medicines of value to patients with cancer.
Kamran Alam
Chief Financial Officer of Taysha Gene Therapies
Kamran Alam is the Chief Financial Officer at Taysha Gene Therapies.
Follow Kamran Alam:
About Taysha Gene Therapies: Taysha Gene Therapies develops treatments to eradicate severe and life-threatening monogenic diseases of the central nervous system.
O. James Sterling
Chief Financial Officer of Renalytix AI
Follow O. James Sterling:
About Renalytix AI: RenalytixAI is a developer of artificial intelligence (AI) enabled clinical diagnostic solutions for kidney disease.
Roger Sawhney
Chief Financial Officer of Omega Therapeutics
Roger Sawhney is the Chief Financial Officer at Omega Therapeutics.
Follow Roger Sawhney:
About Omega Therapeutics: Omega Therapeutics offers a proprietary epigenomic programming platform.
Isaac Miller
CFO, Co-Founder of Cresilon, Inc.
Isaac co-founded Suneris and is responsible for all financial operations. He directs Suneris’ business initiatives and manages investor relations. Through financial analysis and forecasting, Isaac devises and implements strategic financial plans that maximize assets and foster growth at Suneris. Currently, he is an Innovation Consultant at NYU Polytechnic School of Engineering. Isaac holds a BS in Finance and Management from NYU Stern School of Business.
Follow Isaac Miller:
About Cresilon, Inc.: Cresilon is a medical device company that produces and markets solutions for trauma care.
Martin Smiley
General Counsel & CFO of mPhase Technologies
Martin Smiley is a General Counsel & CFO at mPhase Technologies.
Follow Martin Smiley:
About mPhase Technologies: mPhase Technologies develops and commercializes next-generation solutions for telecommunications and nanotechnology applications.
William Harris
CFO of EnGeneIC
Follow William Harris:
About EnGeneIC: EnGeneIC develops and commercializes the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells.
Rahul Parmar
Chief Financial Officer of World Biotechnology
Follow Rahul Parmar:
About World Biotechnology: Synthetic Biology that lowers the cost of industrial bioproduction and biopharmaceuticals
Benjamin Newmark
President & CFO of SolasCure
Benjamin Newmark is the Founder, President, and CFO at SolasCure.
Follow Benjamin Newmark:
About Better.com, SolasCure: Solascure is a biotechnology company focused on the development of fit for purpose, efficacious wound care products.
James Cerveaux
Chief Financial Officer of CDx Diagnostics
Jimmy Cerveaux brings C-level executive experience with deep financial expertise acquired at blue chip companies and as an entrepreneur. He co-founded, led and sold Unicity Eldercare, a successful 150 employee healthcare company located in NY & NJ. Mr. Cerveaux also worked for many years as an Auditor and a Mergers & Acquisitions Consultant at Ernst & Young, and as an equity analyst for a leading investment management firm in the Middle East. He is a graduate of Massachusetts Institute of Technology in Cambridge, MA.
Follow James Cerveaux:
About CDx Diagnostics: CDx Diagnostics develops and provides diagnostic systems intended to prevent cancer by detecting pre-cancerous cells.
Jim Walsh
Chief Financial Officer of Noble Biomaterials
Mr. Walsh has 30 years of business experience and began his career as a certified public accountant. Jim entered the private manufacturing sector in 1983 by joining Instrument Specialties Co., a premier provider of RFI/EMI shielding solutions, where he served in several operational and financial roles. In 2000, Mr. Walsh managed the offering and sale of Instrument Specialties for $285 million. Jim joined Noble in 2005. Jim holds a Bachelor’s degree in accounting from the University of Scranton in Pennsylvania.
Follow Jim Walsh:
About Noble Biomaterials: Noble creates intelligent materials designed to PROTECT, SAVE, HEAL, and IMPROVE LIVES
Mark Corrao
Chief Financial Officer of Kannalife
Follow Mark Corrao:
About Kannalife: Kannalife is a biopharmaceutical company that focuses on innovation in research and development of novel cannabinoid therapeutic agents.
Lawrence A. Kenyon
Chief Financial Officer of Outlook Therapeutics
Lawrence A. Kenyon is the Chief Financial Officer of Outlook Therapeutics.
Follow Lawrence A. Kenyon:
About Outlook Therapeutics: Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing monoclonal antibody biosimilar therapeutics.
Alan A. Bucher,
Chief Financial Officer of Getinge
Alan A. Bucher is the Chief Financial Officer at Getinge.
Follow Alan A. Bucher,:
About Getinge: Getinge identifies customer issues and promotes clinical and economic benefits and follow and support the customer decision process.
Chris Dorsey
CFO and COO of Getinge
Chris Dorsey is the CFO and COO at Getinge.
Follow Chris Dorsey:
About Getinge: Getinge identifies customer issues and promotes clinical and economic benefits and follow and support the customer decision process.
Matt Kapusta
Chief Financial Officer of UniQure
Matt Kapusta joined uniQure as CFO in January 2015 with nearly 20 years of experience in the life sciences industry. Most recently, Matt was Senior Vice President at AngioDynamics responsible for corporate development, strategic planning and national accounts. Prior to AngioDynamics, he served as Vice President, Finance for Smith & Nephew Orthopaedics. Matt’s career also includes more than a decade of investment banking experience focused on emerging life sciences companies. Matt was Managing Director, Healthcare Investment Banking at Collins Stewart, and held various positions at Wells Fargo Securities, Robertson Stephens and PaineWebber. Matt holds a Master of Business Administration from New York University’s Stern School of Business, a Bachelor of Business Administration from University of Michigan’s Ross School of Business and earned his Certified Public Accountant license in 1996 while at Ernst & Young.
Follow Matt Kapusta:
About UniQure: uniQure is focused on the research and early development of human gene-based therapies.
Jack Weinstein
Chief Financial Officer & Treasurer of Relief Therapeutics
Follow Jack Weinstein:
About Relief Therapeutics: Relief Therapeutics is a clinical stage biotechnology company.